Pharvaris N.V. PHVS

PHVS Company Overview

Pharvaris N.V. is a clinical-stage biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disease characterized by recurrent and potentially life-threatening swelling attacks. The company operates within the biotechnology and rare disease therapeutics industries, with its primary focus centered on small-molecule bradykinin B2 receptor antagonists designed to prevent and treat HAE attacks. Pharvaris’ lead programs include deucrictibant formulations for both on-demand and prophylactic use, which represent the company’s primary development and value drivers based on public filings and clinical disclosures.

The company was founded in 2015 by former executives and scientists associated with HAE-focused pharmaceutical development efforts, including individuals previously connected to Shire and related rare disease programs. Pharvaris established its corporate headquarters in Zug, Switzerland, and later listed on Nasdaq under the ticker PHVS. Its strategic positioning is tied to the development of orally administered therapies intended to offer an alternative to injectable HAE treatments currently used in the market. Publicly available company disclosures and industry reporting indicate that Pharvaris seeks differentiation through patient convenience, rapid administration, and lifecycle expansion across acute and preventive treatment settings.